<DOC>
	<DOCNO>NCT00645281</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety tolterodine impact primary symptom complaint patient OAB .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Tolterodine Specific Symptoms Adult Patients With Overactive Bladder .</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>selfreported symptom OAB â‰¥ 3 month prior screen OAB define urinary frequency ( minimum 8 micturition per 24 hour ) urgency ( define strong sudden desire urinate ) urge incontinence minimum 2 episode 3 day , confirm micturition diary screen baseline patient describe degree bothersomeness bothersome OAB symptom `` moderately `` , `` great deal `` , `` great deal '' per OAB Bother Rating Scale condition would contraindicate usage tolterodine daily , include : narrow angle glaucoma , urinary retention , gastric retention clinically significant local urinary tract pathology could mimic symptom OAB , infection hematuria stress incontinence , functional , overflow incontinence determine investigator symptomatic acute urinary tract infection ( UTI ) runin period , recurrent UTIs define treatment symptomatic UTI &gt; 3 time 12 month prior participation clinical trial clinically significant urinary tract obstruction history low urinary tract surgery ( e.g . prostate removal destruction , incontinence surgery ) within past 3 month clinically significant interstitial cystitis significant bladder pain syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>